Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: A time series analysis

Ophthalmology

Volumn 119, Issue 8, 2012, Pages 1604-1608

  Campbell, Robert J ^a,d,f   Bell, Chaim M ^b,c,d,e   Paterson, J Michael ^c,d,h   Bronskill, Susan E ^c,d   Moineddin, Rahim ^b,d   Whitehead, Marlo ^a,d   Gill, Sudeep S ^a,d,g  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f HOTEL DIEU HOSPITAL   (Canada)

^g St Mary's of the Lake Hospital   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; ARTICLE; BRAIN ISCHEMIA; CANADA; DIABETES MELLITUS; DRUG UPTAKE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHOTODYNAMIC THERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SEX DIFFERENCE; TIME SERIES ANALYSIS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; RISK ASSESSMENT; STROKE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864464292     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.05.028     Document Type: Article

References (24)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. A. Tufail, P.J. Patel, C. Egan ABC Trial Investigators Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study [report online] BMJ 340 2010 c2459 http://www.bmj.com/ highwire/filestream/362622/field-highwire-article-pdf/0.pdf Accessed April 19, 2012
3. R.J. Campbell, S.E. Bronskill, C.M. Bell Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis Arch Ophthalmol 128 2010 359 362
4. Roche Business Report 2011 2011 F. Hoffmann-La Roche Ltd 66 www.roche.com/investors/annual-reports.htm Accessed May 11, 2012
5. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
6. F.A. Scappaticci, J.R. Skillings, S.N. Holden Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239
7. T. Ueta, Y. Yanagi, Y. Tamaki, T. Yamaguchi Cerebrovascular accidents in ranibizumab [letter] Ophthalmology 116 2009 362
8. L.H. Curtis, B.G. Hammill, K.A. Schulman, S.W. Cousins Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration Arch Ophthalmol 128 2010 1273 1279
9. J.I. Williams, W. Young A summary of studies on the quality of health care administrative databases in Canada V. Goel, J.I. Williams, G.M. Anderson, The ICES Practice Atlas: Patterns of Health Care in Ontario 2nd ed. 1996 Canadian Medical Association Ottawa 339 345 http://www.ices.on.ca/file/ Practice2-appendix.pdf Accessed April 19, 2012
10. A.R. Levy, B.J. O'Brien, C. Sellors Coding accuracy of administrative drug claims in the Ontario Drug Benefit database Can J Clin Pharmacol 10 2003 67 71
11. D.N. Juurlink, C. Preyra, R. Croxford et al. Canadian Institute for Health Information Discharge Abstract Database: a validation study 2006 Institute for Clinical Evaluative Sciences Toronto http://www.ices.on.ca/file/ cihi-dad-reabstractors-study.pdf Accessed April 19, 2012
12. R.A. Kokotailo, M.D. Hill Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10 Stroke 36 2005 1776 1781
13. J.E. Hux, F. Ivis, V. Flintoft, A. Bica Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm Diabetes Care 25 2002 512 516
14. K. Tu, N.R. Campbell, Z.L. Chen et al. Accuracy of administrative databases in identifying patients with hypertension Open Med [serial online] 1 2007 e18 e26 http://www.openmedicine.ca/article/view/17/35 Accessed April 19, 2012
15. M. Mamdani, K. Sykora, P. Li Reader's guide to critical appraisal of cohort studies: 2 Assessing potential for confounding BMJ 330 2005 960 962
16. A.K. Wagner, S.B. Soumerai, F. Zhang, D. Ross-Degnan Segmented regression analysis of interrupted time series studies in medication use research J Clin Pharm Ther 27 2002 299 309
17. A.I. McLeod, E.R. Vingilis Power computations in time series analyses for traffic safety interventions Accid Anal Prev 40 2008 1244 1248
18. F. Zhang, A.K. Wagner, D. Ross-Degnan Simulation-based power calculation for designing interrupted time series analyses of health policy interventions J Clin Epidemiol 64 2011 1252 1261
19. C. Sun, R. Klein, T.Y. Wong Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study Ophthalmology 116 2009 1913 1919
20. B.A. Nguyen-Khoa, E.L. Goehring Jr, W. Werther Hospitalized cardiovascular diseases in neovascular age-related macular degeneration Arch Ophthalmol 126 2008 1280 1286
21. R. Klein, B.E. Klein, S.C. Tomany, K.J. Cruickshanks The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study Ophthalmology 110 2003 636 643
22. S.L. Alexander, W.T. Linde-Zwirble, W. Werther Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients Ophthalmology 114 2007 2174 2178
23. Y. Duan, J. Mo, R. Klein Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans Ophthalmology 114 2007 732 737
24. T.Y. Wong, R. Klein, C. Sun Atherosclerosis Risk in Communities Study Age-related macular degeneration and risk for stroke Ann Intern Med 145 2006 98 106